List view / Grid view


NGS In-Depth Focus 2017

12 September 2017 | By

Next-generation sequencing is a crucial part of the scientist's toolkit. This in-depth focus compares the strengths and weaknesses of a range of NGS technologies and examines the benefits and challenges of using it in infectious disease diagnosis...

Expert view: Overcoming NGS obstacles

12 September 2017 | By

Using next-generation sequencing techniques enables pharmaceutical companies to explore the molecular landscape of disease initiation and progression with unprecedented clarity. Dr Sam Rulli, Product Manager at QIAGEN, provides his insight into the major challenges researchers face...

Visualising the effects of targeted therapies on patient tumours

11 September 2017 | By

The development of technology that can ‘see’ inside our bodies is one of the great achievements of modern medicine.1 For over 100 years, doctors have used imaging methods for this very reason to help guide patient care. Initially, two-dimensional x-ray pictures of bones and chests were used to help diagnose…

Mass spectrometry imaging in drug discovery

11 September 2017 | By ,

Mass spectrometry imaging allows direct measurement of the molecular composition of a sample. It can be used to image the spatial distribution of exogenous drugs and endogenous metabolites simultaneously over the surface of tissue sections or small biopsy, allowing new insights into both compound efficacy and safety during drug discovery.

Assays In-Depth Focus 2017

8 September 2017 | By

This in-depth focus looks at improving assay techniques to produce more detailed results using crystallography. It also covers some aspects of high-content screening assay development that are critical to successful implementation...

Drug Target Review – Issue #3 2017

6 September 2017 | By

Included in this issue: The importance of industry partnerships; Calcilytics as potential novel therapeutic treatments to halt Alzheimer's disease; Accelerating neuroscience research with flow cytometry...

Inflammatory biomarkers as a herbal anti-arthritic drug discovery tool

11 July 2017 | By , , , , ,

Rheumatoid arthritis (RA) is joint-related, immune-based inflammatory disarray that affects almost 1% of the world’s population. The most evidenced pathogenesis is T-cell activation, which leads to clusters of differentiation (CD) in the T-cells and concurrently increases various inflammatory biomarkers.